Journal article

An open label pilot trial of low-dose lithium for young people at ultra-high risk for psychosis

SM Rice, B Nelson, GP Amminger, SM Francey, LJ Phillips, MB Simmons, M Ross, HP Yuen, AR Yung, K O'Gorman, PD McGorry, SJ Wood, GE Berger

Early Intervention in Psychiatry | WILEY | Published : 2024

Abstract

Aim: Lithium, even at low doses, appears to offer neuroprotection against a wide variety of insults. In this controlled pilot, we examined the safety (i.e., side-effect profile) of lithium in a sample of young people identified at ultra-high risk (UHR) for psychosis. The secondary aim was to explore whether lithium provided a signal of clinical efficacy in reducing transition to psychosis compared with treatment as usual (TAU). Methods: Young people attending the PACE clinic at Orygen, Melbourne, were prescribed a fixed dose (450 mg) of lithium (n = 25) or received TAU (n = 78). The primary outcome examined side-effects, with transition to psychosis, functioning and measures of psychopatholo..

View full abstract